Silence Therapeutics plc

Regulatory Filings • Jun 1, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7909O

Silence Therapeutics PLC

01 June 2015

1 June 2015

Silence Therapeutics plc

Result of General Meeting

Silence Therapeutics plc, AIM: SLN, ("Silence" or "the Company"), a leader in the development and delivery of novel RNA therapeutics, announces that at its Annual General Meeting held earlier today, all resolutions were duly passed.

Enquiries:

Silence Therapeutics plc	+44 (0)20 3700 9711
Timothy Freeborn, Finance Director & Company Secretary
Rozi Morris, Communications Manager
Canaccord Genuity Limited (Nominated Adviser and Joint Broker)	+44 (0)20 7523 8350
Dr Julian Feneley/Peter Stewart/Cara Griffiths
Peel Hunt LLP (Joint Broker)	+44 (0)20 7418 8900
James Steel/ Oliver Jackson

About Silence Therapeutics (www.silence-therapeutics.com) 

Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGSSSFSFFISELM